WPLYW CETUKSYMABU NA PROCES APOPTOZY I FAZY CYKLU KOMOREK RAKA PIERSI IN VITRO
Author(s): Jolanta Rzymowska, Agnieszka Zbyrad
The aim of the study was to check how cetuximab affects the cell cycle and apoptosis of breast cancer cells. The study was conducted on primary breast cancer cell lines and non-neoplastic cell lines derived from samples collected from patients with histopathologically diagnosed Tp1-2 Np0 Mp0 ductal carcinoma. The effect of this chemotherapeutic agent on cells in the G1, S, G2/M cell cycle phases and on apoptosis of these cells was analyzed in a flow cytometer. Cetuximab, a monoclonal antibody, at a dose of 10 and 100 μg/mL of the culture medium was used for the study. Cetuximab is capable of inducing apoptosis and inhibiting cancer cells in the S, and G2/M cell cycle phases. This cytostatic agent can constitute a potential strategy in phase-dependent treatment of breast cancer. However, it is not effective enough to be used in monotherapy.
Share this article
Submitted PhD thesis in Biotechnology at GITAM University, Vizag.
The Past Head, General Administration of Pharmaceutical Care at Ministry of Health,
Saudi Arabia Critical Care/TPN
Clinical Pharmacist Ministry of Health,
Riyadh, Saudi Arabia.
Department of Radiation Oncology
Asahi University Hospital
Gifu city, Gifu, Japan
Maher Abdel Fattah Al-Shayeb
Department of Surgical Sciences, Ajman University, UAE
Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)
Citations : 61
- Euro Pub
- Google Scholar
- Medical Project Poland
- Cancer Index
- Gdansk University of Technology, Ministry Points 20